TTK Healthcare Limited has informed the Exchange that Board of Directors at its meeting held on May 23, 2025, recommended Final Dividend of Rs. 10 per equity share.
TTKHLTCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts less than Nifty Microcap 250 and 1.1 pts less than its Diversified peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
TTK Healthcare's Board, at its May 23, 2025 meeting, recommended a final dividend of Rs. 10 per share (100% on face value of Rs. 10) for FY25, payable within 30 days of the AGM scheduled for July 25, 2025. The company reported FY25 revenue from operations of Rs. 80,149 lakhs, up 6.5% from Rs. 75,279 lakhs in FY24. Profit after tax jumped nearly 30% to Rs. 8,166 lakhs (from Rs. 6,284 lakhs), with EPS rising to Rs. 57.79 from Rs. 44.47. Results include a net exceptional gain of Rs. 1,391 lakhs — a Rs. 1,977 lakh profit from selling leasehold land at Mahindra World City, Chennai, partly offset by a Rs. 586 lakh write-off of male contraceptive inventory meant for the USAID export program that was cancelled. Statutory auditors PKF Sridhar & Santhanam LLP issued an unmodified opinion, and M/s Geeyes & Co. was appointed as Cost Auditor for FY26.
Strong earnings growth (driven partly by a one-time land sale gain) and a consistent 100% dividend payout are positive for shareholders. The 30% PAT rise may lift sentiment, though investors should note that core operations grew more modestly (~12% in PBT before exceptional items) and the USAID-related inventory write-off highlights some segment-level risk.